REG - BiVictriX Therapcts. - US Patent Granted

Bivictrix TherapeuticsAnnouncement

23/08/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230823:nRSW1361Ka&default-theme=true

RNS Number : 1361K  BiVictriX Therapeutics PLC  23 August 2023

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE EU
REGULATION 596/2014 AS IT FORMS PART OF THE UK LAW BY VIRTUE OF THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT
VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN
THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

US Patent Granted Providing Broad Protection for BVX001

Alderley Park, 23 August 2023 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a differentiated approach to develop
next-generation cancer therapies with substantially improved cancer cell
selectivity and anti-cancer activity, announces that the United States Patent
and Trademark Office ("USPTO") has granted a patent providing broad protection
for the Company's lead asset, BVX001.

 

The claims granted within this patent (patent number US11,732,040), which
belongs to the wider patent family "Therapy" currently being prosecuted in
eight territories worldwide, provides ultimate broad protection for the lead
therapeutic asset, BVX001, at the antigen level.

 

The claims granted in the United States provide broad protection for an
antibody-based therapeutic attached to a cell-killing payload, such as an
alternative Antibody Drug Conjugate ("ADC") therapy or any akin therapeutic,
which binds to the Company's Bi-Cygni® twin antigen fingerprint comprising
CD7 x CD33, for use in treating of a CD7(+)CD33(+) haematological malignancy.
The coverage extends beyond the Company's lead indication of Acute Myeloid
Leukaemia ("AML"), providing protection across any haematological cancer type
which may be positive for CD7 and CD33. This is true irrespective of the
therapeutic format employed, including use of alternative antibody sequences,
alternative antibody formats and/or alternative cell killing payloads, which
often represent routes taken by third parties to develop a competitive
therapeutic. Taken together, these granted claims represent a very broad and
commercially favourable position for BiVictriX.

 

Further to the US patent issue, which follows the issuance of a Notice of
Allowance from the USPTO, announced in July 2023
(https://bivictrix.com/news/positive-final-data-in-second-preclinical-efficacy-study/)
, BiVictriX confirms receipt of an additional Notice of Allowance from the
Japanese Patent Office. The notice relates to the Japanese patent (publication
number JP2021504469) which also forms part of the wider patent family,
"Therapy". It is anticipated that this patent will be granted in Japan in the
coming weeks, providing further protection for BVX001 at the broadest level.
BiVictriX is currently seeking approval for this patent family in an
additional six jurisdictions worldwide, with further patent grants expected in
the forthcoming months.

 

Tiffany Thorn, CEO of BiVictriX commented: "I am excited to announce that our
first patent has been granted in the United States. This patent relates to our
broadest patent family, providing robust protection for BVX001 at the antigen
level, across multiple cancer types, and acts as a key milestone for the
Company demonstrating the breadth of patent protection we can achieve with the
Bi-Cygni® approach. This patent grant is expected to be the first of many as
we continue to prosecute the wider patent family in seven further
jurisdictions worldwide, creating a robust patent protected portfolio.

 

Barbara Fleck, European Patent Attorney and Partner at Appleyard Leads IP LLP
commented: "I am very pleased to see that the USPTO has issued BiVictriX's
patent with broad claims to methods for treating a CD7(+)CD33(+)
haematological malignancy by administering a cell inhibiting agent linked to a
cytotoxin that bispecifically binds to CD33 and CD7. Obtaining such broad
claims in the antibody space is challenging and this not only validates
BiVictriX's Bi-Cygni® ADC technology for the treatment of AML, but also
provides the Company with broad US patent coverage in a competitive space."

 

ENDS

 

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman             Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)    Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)           Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Namrata Taak,                     Tel: +44 (0) 20 3709 5700

 Max Bennett, Emmalee Hoppe                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

 

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical
experience and its proprietary discovery engine to advance a new class of
highly cancer-selective, next-generation precision cancer therapies in one of
the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni®
Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for prolonged
dosing and greater efficacy in the clinic. The Company is advancing its
pipeline to deliver the future of cancer care across a broad range of
haematological and solid cancer indications in areas of high unmet medical
need.

 

Find out more at www.bivictrix.com (http://www.bivictrix.com/)  and connect
with us on LinkedIn
(https://www.linkedin.com/company/bivictrix-therapeutics-plc/)  and
Twitter @BiVictriX (https://twitter.com/BiVictriX) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZGZRLZMGFZM